Difficult‐to‐express antigen generation through a co‐expression and disassociation methodology

Author:

Lieu Ricky1,Chao Grace1,Kennedy Emma1,Sauder J. Michael2,Narayanasamy Prabakaran1,Pustilnik Anna2,Thangaraju Adithi2,Ho Carolyn1,Pedroza Mariah J.3,Ruiz Diana1,Yang Xiaomin1ORCID

Affiliation:

1. Biotechnology Discovery Research, Eli Lilly and Company Lilly Biotechnology Center San Diego California USA

2. Discovery Chemistry Research and Technologies, Eli Lilly and Company Lilly Biotechnology Center San Diego California USA

3. Lilly On‐site Support, Eurofins Lancaster Laboratories PSS Lancaster Pennsylvania USA

Abstract

AbstractExtracellular domain (ECD) antigens are crucial components for antibody discovery, in vitro assays, and epitope mapping during therapeutical antibody development. Oftentimes, those antigens are difficult to produce while retaining the biologic function/activity upon extracellular secretion in commonly used expression systems. We have developed an effective method to cope with the challenge of generating quality antigen ECDs. In this method, a monoclonal antibody (Mab) or antibody fragment antigen‐binding (Fab) region acts as a “chaperone” to stabilize the antigen ECD through forming an antibody:antigen complex. This methodology includes transient co‐expression of the complex in Chinese hamster ovary cells and then dissociation of the purified complex into individual components by low pH treatment in the presence of arginine. The antigen is then separated from the chaperone on a preparative size exclusion chromatography (pSEC) followed by an optional affinity chromatography process to remove residual Mab or Fab. We demonstrate this co‐expression/disassociation methodology on two difficult‐to‐express antigen ECDs from cluster‐of‐differentiation/cytokine family and were successful in producing stable, biologically active antigens when the common methods using Histidine‐tagged and/or Fc‐fused protein failed. This can be applied as a general approach for antigen production if a Mab or binding partner is available.

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Biotechnology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3